MedTrace Logo

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

NCT02123004 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2015-02-25

No results posted yet for this study

Summary

1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI) patients receiving percutaneous coronary intervention.
2. Ticagrelor can reduce the serum levels of inflammatory biomarkers both in coronary and in peripheral venous in patients with ST-segment elevation myocardial infarction(STEMI).

Conditions

  • ST-Segment Elevation Myocardial Infarction

Interventions

DRUG

Ticagrelor

180mg loading dose for one day ,and then 90mg per day for 4 weeks

DRUG

Clopidogrel

300mg loading dose for one day ,and then 75mg per day for 4 weeks

Sponsors & Collaborators

  • Jinan Central Hospital

    lead OTHER

Principal Investigators

  • Su Guohai, Doctor · Jinan Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02123004 on ClinicalTrials.gov